



2000-2002 Contributions

- 2002 – Present Dean Kereiakes. Editorial Board, Circulation
- 2002 - Present
Medicine Dean Kereiakes. Editorial Board – Reviews in Cardiovascular
Section Editor (New Drugs and Devices)
- 2000 - Present Dean Kereiakes. Editorial Board, American Journal of Cardiology

Bin JP, **Pelberg RA**, Wei K, Le DE, Goodman NC, Kaul S. Dobutamine versus dipyridamole for inducing reversible perfusion defects in chronic multivessel coronary artery stenosis. *J Am Coll Cardiol.* 2002 Jul 3;40(1):167-74.

Bin JP, Le E, **Pelberg RA**, Coggins MP, Wei K, Kaul S. Mechanism of inducible regional dysfunction during dipyridamole stress. *Circulation.* 2002 Jul 2;106(1):112-7.

Pelberg RA, Spotnitz WD, Bin JP, Le E, Goodman NC, Kaul S. Mechanism of myocardial dysfunction in the presence of chronic coronary stenosis and normal resting myocardial blood flow: clinical implications. *J Am Soc Echocardiogr.* 2001 Nov;14(11):1047-56.

Bin J, Wei K, **Pelberg RA**. Assessment of the effects of dipyridamole and dobutamine on coronary microcirculation using myocardial contrast echocardiography. *Zhonghua Yi Xue Za Zhi.* 2000 Dec;80(12):939-42.

Bin JP, **Pelberg RA**, Wei K, Coggins M, Goodman NC, Kaul S. Relation between regional function and coronary blood flow reserve in multivessel coronary artery stenosis. *Am J Physiol Heart Circ Physiol.* 2000 Dec;279(6):H3058-64.

Kereiakes DJ, Broderick TM, Howard WL, Anderson LC, Weber M, Mitts DL. Successful long-term therapy following saphenous vein-covered stent deployment for atherosclerotic coronary aneurysm. *Cathet and Cardiovasc Interv* 2002;55:100-104.

Seshiah PN, **Kereiakes DJ**, Vasudevan SV, Lopes N, Su BY, Flavahan NA, Goldschmidt-Clermont PJ. Activated monocytes induce smooth muscle cell death – Role of Macrophage colony-stimulating factor and cell contact. *Circulation* 2002;105:174-180.

Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hockman JS, Jones RH, **Kereiakes D**, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE3rd, Steward DE, Therous P, Gibbons RJ, Alpert JS, Faxon DP, Fuster Intravenous, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). *J Am Coll Cardiol* 2002;40:1366-74.

Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hockman JS, Jones RH, **Kereiakes D**, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE3rd, Steward DE,

Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster Intravenous, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – 2002: summary article: a report of the American College of Cardiology/American Heart Association on practice guidelines (Committee on the Management of Patients with Unstable Angina). *Circulation* 2002;106:1893-900.

Tamburino C, Russo G, Nicosia A, Galassi AR, Foti R, Grasso A, Calvi V, **Kereiakes DJ**, Giuffrida G. Prophylactic abciximab in elective complex coronary stenting: results of a randomized trial. *J Invas Cardiol* 2002;14:72-79.

Mazur W, Kaluza GL, Sapp S, Balog, C, Topol EJ, Mark DB, Ellis SG, **Kereiakes DJ**, Lincoff AM, Kleiman NS. Glycoprotein IIb/IIIa inhibition with abciximab and post-procedural risk assessment: lesson from EPISTENT and implication for ad hoc use of GP IIb/IIIa antagonists. *Am Heart J* 2002;143:594-601.

Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Combination antiplatelet therapy following brachytherapy with restenting: “It ain’t over ‘til the fat lady sings” *J Invas Cardiol* 2002;14:115-117.

Young JJ, **Kereiakes DJ**. LMWH in percutaneous coronary intervention: ready for prime time? *ACC Current Journal Review* 2002:

Wheeler GL, Braden GA, Steinhubl SR, **Kereiakes DJ**, Kotte-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC. The Ultegra-RPFA: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. *Am Heart J* 2002;143:602-11.

Young JJ, **Kereiakes DJ**, Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice. *J Intervent Cardiol* 2002;15:115-120.

Tamberella MR, Bhatt DL, Chew DP, **Kereiakes DJ**, Topol EJ, Steinhubl SR on behalf of the GOLD investigators. Relation of platelet inactivation with intravenous GP IIb/IIIa antagonists to major bleeding (from the GOLD study). *Am J Cardiol* 2002;89:1429-1431.

Topol EJ, Lincoff AM, **Kereiakes DJ**, Kleiman NA, Cohen EA, Ferguson JJ, Tchong JE, Anderson KM, Barnathan ES, Califf RM for the EPIC, EPILOG and EPISTENT investigators. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. *Am J Med* 2002;113:1-6.

Young JJ, **Kereiakes DJ**. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: “IIb or Not IIb, What is the Question?” *J Invas Cardiol* 2002;14:404-410.

Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, **Kereiakes DJ**, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P. ACC/AHA 2002 Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article. *J Am Coll Cardiol* 2002;40:1366-74.

Kereiakes DJ, Lincoff AM, Anderson K, Achenbach R, Patel K, Barnathan E, Califf RM, Topol EJ on behalf of the EPIC, EPILOG and EPISTENT investigators. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. *Am J Cardiol* 2002;90:628-630.

Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch K, Kleiman NS, Moliterno D, Steg PG, Teirstein P, Van deWerf F, Wallentin L. Low-molecular-

weight heparin therapy for non-ST elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus". *Am Heart J* 2002;144:615-624.

Prpic R, Teirstein PS, Reilly JP, Moses JW, Tripuraneni P, Lansky American Journal of Cardiology, Giorgianni JA, Jani S, Wong SC, Fish RD, Ellis S, Holmes DR, **Kereiakes DJ**, Kung RE, Leon MB. Long-term outcomes of patients treated with repeat percutaneous coronary intervention after failure of gamma brachytherapy for the treatment of in-stent restenosis. *Circ* 2002;106:2340-2345.

Nakada MT, Sassoli PM, Tam SH, Nedelman MA, Jordan RE, **Kereiakes DJ**. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GP IIb/IIIa antagonists in non-human primates. *J Thrombosis and Thrombolysis* 2002;14:15-24

Choo JK, Young JJ, **Kereiakes DJ**. A guide to drug use during percutaneous coronary intervention. *Drugs* 2002;62:2589-601.

Lepor NE, Madyoon H, **Kereiakes DJ**. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era. *Reviews in Cardiovascular Medicine* 2002;3(suppl 5):S38-S50.

O'Neill W, **Kereiakes DJ**, Braden G, Ramee SR. In-stent restenosis: treatment controversies. *J Invas Cardiol* 2002;14: Supplement D (October).

Kereiakes DJ, McDonald MA, Broderick TM, Roth EM, Whang DD, Martin LH, Howard W, Schneider J, Shimshak TM, Abbottsmith, CA. Platelet glycoprotein IIb/IIIa receptor blockers: an appropriate use model for expediting care in acute coronary syndromes. *Am Heart Journal* 2000;139:S53-S60 (supplement).

Kereiakes DJ, Broderick TM, Roth EM, Mueller M, Anderson LC, Howard W, Blanck C, Abbottsmith CA. High platelet count in platelet rich plasma reduces measured platelet inhibition by abciximab but not small molecule glycoprotein IIb/IIIa receptor antagonists. *J Thromb Thrombolysis* 2000;9:149-155.

Gurbel PA, **Kereiakes DJ**, Dalesandro MR, Bahr RD, O'Connor CM, Serebruany VL. Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. *Am Heart J* 2000;139:320-8.

Serebruany VL, **Kereiakes DJ**, Dalesandro MR, Gurbel PA. Model of flow cytometer markedly affects platelet - bound p-selectin expression in patients with chest pain. Are we comparing apples with oranges? *Thrombosis Research* 1999;96:51-56.

Kereiakes DJ, Midei M, Hermiller J, O'Shaughnessy C, Schlofmitz R, Yakubov S, Fink S, Hu F, Nishimura N, Sievers M, Valentine ME, Broderick TM, Lansky A, Moses J. Procedural and late outcomes following MULTI-LINK DUET coronary stent deployment. *Am J Cardiol*, 1999;84:1385-1390.

Hendel RC, Henry TD, Rocha-Singh K, Isner JM, **Kereiakes DJ**, Giordano FJ, Simons M, Bonow RO. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion. Evidence for a dose-dependent effect. *Circulation* 2000;101:118-121.

Kereiakes DJ. Into the third millennium: the changing face of cardiology practice. *J Cardiovasc Mgmt* 1999;20-23.

Kereiakes DJ, Broderick TM, Abbottsmith CA, Shimshak TM. Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: a new look at an old problem. *J Invas Cardiol* 2000;12:95-98.

Madan M, **Kereiakes DJ**, Hermiller JB, Rund MM, Tudor G, Anderson L, McDonald MB, Berkowitz SD, Sketch MH, Phillips HR III, Tchong JE. Efficacy of Abciximab Readministration in Coronary Intervention. *Am J Cardiol* 2000;85:435-440.

Kereiakes DJ, Fry E, Matthai W, Niederman A, Barr L, Brodie B, Zidar J, Casale P, Christy G, Moliterno D, Lengerich R, Broderick T, Shimshak T, Cohen M. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE" Guys finish first. *J Invas Cardiol* 2000;12:1A- 5A (supplement).

Tramuta DA, **Kereiakes DJ**, Dippel EJ, Lengerich R, Broderick TM, Abbottsmith CW, Whang DD, Roth EM, Schneider JF, Howard W, Shimshak TM. Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care? *Journal of Invasive Cardiology* 2000;12:3C-6C (supplement).

Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM. Iib's are not Iib's. *Am J Cardiol* 2000;85;23C-31C (supplement).

Kereiakes DJ, Grines C, Fry E, Esente A, Barr L, Matthai W, Shimshak TS, Broderick M, Cohen M. Combination enoxaparin and abciximab during percutaneous coronary intervention: a new standard of care? *Current Interventional Cardiology Reports* 2000;2;157-164.

Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai WH, Vliestra RE, Brinker JA, **Kereiakes DJ**, Muhlestein JB, Lansky A, Popma JJ, Buchbinder M, Hirshfeld JW Jr. A randomized trial of contrast media utilization in high risk PTCA (The COURT Trial). *Circulation* 2000;101:2172-2177.

Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. *Circulation* 2000;101:2788-2794.

Kereiakes DJ, Berkowitz SC, Lincoff AM, Tchong JE, Wolski K, Achenbach R, Melsheimer R, Anderson K, Califf RM, Topol EJ. Clinical correlates and clinical course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. *Am Heart Journal* 2000,140:74-80.

Kereiakes DJ, Linnemeier TJ, Baim DS, Kuntz R, O'Shaughnessy C, Hermiller J, Fink S, Lansky A, Nishimura N, Broderick TM, Popma J. Usefulness of stent length in predicting in-stent restenosis (The MULTI-LINK stent trials). *Am J Cardiol* 2000;86:336-341.

Grines CL, **Kereiakes DK**. Antithrombotic therapy in the catheterization laboratory: interim analysis of the NICE trials. *European Heart Journal* 2000;2(suppl):F12-F15.

Harrington RA, Armstrong PW, Graffagnino C, Vande Werf F, **Kereiakes DJ**, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Califf RM, Topol EJ for the Anti PLAtelet Useful Dose (APLAUD) study investigators. Dose-finding, safety, tolerability of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. *Circulation* 2000;102:728-735.

Kereiakes DJ. Unstable Angina: When Should We Intervene? *Current Controlled Trials in Cardiovasc Med* 2000;1:9-14.

Young JJ, **Kereiakes DJ**. Combination low-molecular weight heparin and glycoprotein IIb/IIIa inhibition during coronary intervention. *Acute Coronary Syndromes* 2000;3:62

Gurbel PA, **Kereiakes DJ**, Serebrauny VL. Soluble p-selection is not a surrogate marker for platelet p-selection: evidence from a multicenter chest pain study group. *J Thrombosis & Thrombolysis* 2000;10:15-22.

Kereiakes DJ, Obenchain RL, Barber BL, Smith A, McDonald M, Broderick TM, Runyon JP, Shimshak TM, Schneider JF, Hattemer CH, Roth EM, Whang DD, Cocks D. Abciximab provides cost effective survival advantage in high volume interventional practice. *Am Heart J* 2000;140:603-10.

Young JJ, **Kereiakes DJ**, Grines CL, for the National Investigators Collaborating on Enoxaparin (NICE) Investigators. Low-molecular weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. *J Invas Cardiol* 2000;12(Suppl E):#14-E18.

Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, **Kereiakes DJ**, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, III, Steward DE, Theroux P. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2000;36:970-1062.

Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, **Kereiakes DJ**, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, III, Steward DE, Theroux P. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. *Circulation* 2000;102:1193-1209.

Antman EM, **Kereiakes DJ**. Antithrombotic therapy in unstable angina/non-ST elevation myocardial infarction: the evolving role of low-molecular-weight heparin. *J Invas Cardiol* 2000;12(Suppl E):E1-E4.

Young JJ, **Kereiakes DJ**. Abciximab: cost-effective survival advantage in clinical trials and clinical practice. *Am Heart J* 2000;140:S148-53.

Gurbel PA. **Kereiakes DJ**, Atar D, Serebrauny VL. Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. *Scand Cardiovasc J* 2000;34:53-58..

Kereiakes DJ, Young JJ, Broderick TM, Shimshak TM, Abbottsmith CW. Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute coronary syndromes. *Am J Cardiol* 2000;86:10M-17M.

Baim DS, Cutlip DE, Midei M, Linnemeier TJ, Schreiber T, Cox D, **Kereiakes DJ**, Popma JJ, Robertson L, Prince R, Lansky AJ, Ho KKL, Kuntz RE for the ASCENT investigators. Final results of a randomized trial comparing the MULTI-LINK stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. *Am J Cardiol* 2001;87:157-162.

Baim DS, Cutlip DE, O'Shaughnessy CD, Hermiller JB, Midei M, **Kereiakes DJ**, Giambartolomei A, Katz S, Lansky AJ, Fitzpatrick M, Popma JJ, Ho KKL, Leon MB, Kuntz RE for the NIRVANA investigators. Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. *Am J Cardiol* 2001;87:152-156.

Leon MB, Teirstein PS, Moses JW, Lansky AJ, Tripuraneni P, Jani S, Wong SC, Willerson JT, Ellis S, Holmes DR, **Kereiakes DJ**, Kuntz RE. A multicenter randomized trial of localized

intracoronary gamma radiation therapy to inhibit restenosis after stenting. *New Engl J Med* 2001;344:250-256.

Kereiakes, DJ, Kleiman NS, Fry E, Mwawasi G, Lengerich R, Maresh K, Burkert ML, Aquilina JW, DeLoof M, Broderick TM, Shimshak TM. Dalteparin in combination with abciximab during percutaneous coronary intervention. *Am Heart J* 2001;141:348-52.

Dippel EJ, **Kereiakes DJ**, Tramuta DA, Broderick TM, Shimshak TM, Roth EM, Hattemer CJ, Runyon JP, Whang DD, Schneider JF, Abbottsmith CW. Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management. *Cathet Cardiovasc Intervent* 2001;52:279-286.

Reddy MS, Carmody TJ, **Kereiakes DJ**. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. *Cathet & Cardiovasc Interv* 2001;52:486-488.

Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, Barr L, Matthai W, Todd M, Broderick TM, Rubinstein R, Fareed J, Santoian E, Neiderman A, Brodie B, Zidar J, Cohen M for the NICE 1 and NICE 4 investigators. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. *J Invas Cardiol* 2001;13:272-278.

Steinhuyl SR, Talley JD, Braden GA, Tchong JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R., Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, **Kereiakes DJ**. Point-of-care measured platelet inhibition correlates with the risk of an adverse cardiac event following percutaneous coronary intervention. Results of the GOLD (AU-assessing Ultegra) multicenter study. *Circulation* 2001;103:2572-2578.

Seshiah PN, **Kereiakes DJ**, Goldschmidt-Clermont P. Platelet glycoprotein IIb/IIIa receptor blockers: class and agent-specific clinical benefits. *Cardiology Special Edition* (in press)

Smith SC, Dove JT, Jacobs AK, Kennedy JW, **Kereiakes DJ**, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines) – Executive Summary. *J Am Coll Cardiol* 2001;37:2215-2238.

Smith SC, Dove JT, Jacobs AK, Kennedy JW, **Kereiakes DJ**, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines – Executive Summary. *Circulation* 2001;103:3019-3041.

Tchong JE, **Kereiakes DJ**, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, Efron MB, Braden GA, on behalf of the ReoPro Readminstration Registry investigators. Abciximab readministration: results of the ReoPro readministration registry. *Circulation* 2001;104:870-875.

Lincoff AM, **Kereiakes DJ**, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers following percutaneous coronary revascularization. *Circulation* 2001;104:163-167.

Foley DP, **Kereiakes DJ**, Riele JAM, Nishimura N, Veldhof S, Yeung A, van Hoogenhuyze, Lansky AM, van Es G, Butryk MJB, Serruys PW on behalf of the US and European DUET investigators. Acute and 6 month clinical and angiographic outcome after implantation of the ACS DUET stent for single vessel coronary artery disease: final results of the European and US ACS MULTI LINK DUET registry. *Catheter Cardiovasc Interv* 2001;54:25-33.

Roe MT, Cura F, Joski PS, Garcia E, Guetta V, **Kereiakes DJ**, Zijlstra F, Brodie BR, Grines CL, Ellis SG. Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction. *Am J Cardiol* 2001;88:170-173.

Furman MI, **Kereiakes DJ**, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL III, Michelson AD. Leukocyte-platelet aggregation and platelet p-selectin and GP IIIa expression following percutaneous coronary intervention: effects of dalteparin or unfractionated heparin in combination with abciximab. *Am Heart J* 2001;142:790-8.

Casterella PJ, **Kereiakes DJ**, Steinhubl SR, Raymond RE, Kottke-Marchant K, Patel K, Mueller M, Rosenthal M, Moliterno DJ, Teirstein PS. The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable. *Cathet Cardiovasc Intervent* 2001;54:497-504.

Choo J, **Kereiakes DJ**. Low molecular weight heparin therapy for percutaneous coronary intervention: a practice in evolution. *J Thromb Thrombolysis* 2001;11:235-246.

Kereiakes DJ, Lorenz T, Young JJ, Kukeilka G, Mueller MN, Nanniazzi-Alaimo L, Phillips DR. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatid and tirofiban. *J Thromb Thrombolysis* 2001;12:123-127.

Kandzari DE, Behar VS, Sketch MH Jr., Kereiakes DJ, Shimshak T, Broderick T, Young J, Runyon JP, Safian RD, Kern M, Colombo A. Extensive thrombus prior to elective percutaneous coronary intervention. *J Invas Cardiol* 2001;13:538-42.

Kereiakes, DJ, Ticlopidine monotherapy following coronary stent deployment: "Penny wise and Pound Foolish". *J Invas Cardiol* 2001;13:437-8

Furman MI, **Kereiakes DJ**, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL 3rd, Michelson AD. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. *Am Heart J*. 2001 Nov;142(5):790-8.

Kereiakes DJ, Broderick TM, Howard WL, Anderson LC, Weber M, Mitts DL. Successful long-term therapy following saphenous vein-covered stent deployment for atherosclerotic coronary aneurysm. *Cathet and Cardiovasc Interv* 2002;55:100-104.

Seshiah PN, **Kereiakes DJ**, Vasudevan SV, Lopes N, Su BY, Flavahan NA, Goldschmidt-Clermont PJ. Activated monocytes induce smooth muscle cell death – Role of Macrophage colony-stimulating factor and cell contact. *Circulation* 2002;105:174-180.

Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hockman JS, Jones RH, **Kereiakes D**, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE3rd, Steward DE, Therous P, Gibbons RJ, Alpert JS, Faxon DP, Fuster Intravenous, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). *J Am Coll Cardiol* 2002;40:1366-74.

Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hockman JS, Jones RH, **Kereiakes D**, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE3rd, Steward DE, Therous P, Gibbons RJ, Alpert JS, Faxon DP, Fuster Intravenous, Gregoratos G, Hiratzka LF,

Jacobs AK, Smith SC Jr. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – 2002: summary article: a report of the American College of Cardiology/American Heart Association on practice guidelines (Committee on the Management of Patients with Unstable Angina). *Circulation* 2002;106:1893-900.

Tamburino C, Russo G, Nicosia A, Galassi AR, Foti R, Grasso A, Calvi V, **Kereiakes DJ**, Giuffrida G. Prophylactic abciximab in elective complex coronary stenting: results of a randomized trial. *J Invas Cardiol* 2002;14:72-79.

Mazur W, Kaluza GL, Sapp S, Balog, C, Topol EJ, Mark DB, Ellis SG, **Kereiakes DJ**, Lincoff AM, Kleiman NS. Glycoprotein IIb/IIIa inhibition with abciximab and post-procedural risk assessment: lesson from EPISTENT and implication for ad hoc use of GP IIb/IIIa antagonists. *Am Heart J* 2002;143:594-601.

Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Combination antiplatelet therapy following brachytherapy with restenting: “It ain’t over ‘til the fat lady sings” *J Invas Cardiol* 2002;14:115-117.

Young JJ, **Kereiakes DJ**. LMWH in percutaneous coronary intervention: ready for prime time? *ACC Current Journal Review* 2002:

Wheeler GL, Braden GA, Steinhubl SR, **Kereiakes DJ**, Kotte-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC. The Ultegra-RPFA: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. *Am Heart J* 2002;143:602-11.

Young JJ, **Kereiakes DJ**, Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice. *J Intervent Cardiol* 2002;15:115-120.

Tamberella MR, Bhatt DL, Chew DP, **Kereiakes DJ**, Topol EJ, Steinhubl SR on behalf of the GOLD investigators. Relation of platelet inactivation with intravenous GP IIb/IIIa antagonists to major bleeding (from the GOLD study). *Am J Cardiol* 2002;89:1429-1431.

Topol EJ, Lincoff AM, **Kereiakes DJ**, Kleiman NA, Cohen EA, Ferguson JJ, Tchong JE, Anderson KM, Barnathan ES, Califf RM for the EPIC, EPILOG and EPISTENT investigators. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. *Am J Med* 2002;113:1-6.

Young JJ, **Kereiakes DJ**. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: “IIb or Not IIb, What is the Question?” *J Invas Cardiol* 2002;14:404-410.

Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, **Kereiakes DJ**, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P. ACC/AHA 2002 Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article. *J Am Coll Cardiol* 2002;40:1366-74.

Kereiakes DJ, Lincoff AM, Anderson K, Achenbach R, Patel K, Barnathan E, Califf RM, Topol EJ on behalf of the EPIC, EPILOG and EPISTENT investigators. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. *Am J Cardiol* 2002;90:628-630.

Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch K, Kleiman NS, Moliterno D, Steg PG, Teirstein P, Van deWerf F, Wallentin L. Low-molecular-

weight heparin therapy for non-ST elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus". Am Heart J 2002;144:615-624.

Prpic R, Teirstein PS, Reilly JP, Moses JW, Tripuraneni P, Lansky American Journal of Cardiology, Giorgianni JA, Jani S, Wong SC, Fish RD, Ellis S, Holmes DR, **Kereiakes DJ**, Kung RE, Leon MB. Long-term outcomes of patients treated with repeat percutaneous coronary intervention after failure of gamma brachytherapy for the treatment of in-stent restenosis. Circ 2002;106:2340-2345.

Nakada MT, Sassoli PM, Tam SH, Nedelman MA, Jordan RE, **Kereiakes DJ**. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GP IIb/IIIa antagonists in non-human primates. J Thrombosis and Thrombolysis 2002;14:15-24

Choo JK, Young JJ, **Kereiakes DJ**. A guide to drug use during percutaneous coronary intervention. Drugs 2002;62:2589-601.

Lepor NE, Madyoon H, **Kereiakes DJ**. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era. Reviews in Cardiovascular Medicine 2002;3(suppl 5):S38-S50.

O'Neill W, **Kereiakes DJ**, Braden G, Ramee SR. In-stent restenosis: treatment controversies. J Invas Cardiol 2002;14: Supplement D (October).

[AFFIRM Investigators. Atrial Fibrillation Follow-up Investigation of Rhythm Management.](#) Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J. 2002;143:991-1001.

Kereiakes DJ. Platelet glycoprotein IIb/IIIa inhibition and atheroembolism during bypass graft angioplasty – a cup half full. Circulation 2002;106:2994-2996.

Abstracts/Letters:

Kereiakes DJ, Grines C, Fry E, Barr L, Matthai W, Broderick TM, Lengerich R, Cohen M, Esente P. Abciximab-enoxaparin interaction during percutaneous coronary intervention: Results of the NICE 1 and 4 trials. J Am Coll Cardiol 2000;35:92A.

Kereiakes DJ, Berkowitz SD, Lincoff AM, Tchong JE, Wolski K, Califf RM, Topol EJ. Abciximab thrombocytopenia: clinical correlates and outcomes. J Am Coll Cardiol 2000;35:91A.

Weaver WD, Harrington RA, Grines CL, Keeley EC, **Kereiakes DJ**, Bittl JA, Grogan DR, Emanuelsson H. Intravenous AR-C69931MX, a novel P2T platelet receptor antagonist in patients undergoing percutaneous coronary interventions: preliminary results from a placebo or active controlled trial. J Am Coll Cardiol 2000;35:36A.

Matthai WH, **Kereiakes DJ**, Grines CL, Siegel JE. Comparative effects of low molecular weight heparin (with and without abciximab) and unfractionated heparin on antithrombin activity during coronary angioplasty. J Am Coll Cardiol 2000;35:34A.

Steinhubl S, Talley D, **Kereiakes D**, Braden G, Tchong J, Casterella P, Moliterno D, Berger P, Popma J, Dangas G, Gallo R, Navetta F, Sane, D, Holmes D, Teirstein P, Topol

E. A prospective multicenter study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention – the GOLD study. *J Am Coll Cardiol* 2000;35:44A.

Leon MB, Teirstein PS, Moises JW, Lansky AJ, Wong SC, Willerson J, Holmes DR, **Kereiakes DJ**, Kluck B, Hermiller JB, George BS, Ellis E, Nawaz DM, Kuntz RE. The Gamma II trial of localized radiation therapy to inhibit restenosis after coronary stenting. *J Am Coll Cardiol* 2000;35:50A.

Bhatt DL, Lincoff AM, Tcheng JE, Califf RM, Lallier PL, Marso SP, Wolski KE, **Kereiakes DJ**, Topol EJ. The impact of abciximab on mortality after multivessel PCI: a striking effect in diabetes. *J Am Coll Cardiol* 2000;35:91A.

Caputo RP, Giambartolomei A, Simons A, Esente P, **Kereiakes DJ**, Ho K, Carrozza JP. Small vessel stenting – comparison of modular vs. slotted tube design. Six month results from the EXTRA trial. *J Am Coll Cardiol* 2000;35:56A.

Bhatt DL, Lincoff AM, **Kereiakes DJ**, Tcheng JE, Godfrey N, Califf RM, Topol EJ. Reduction in the Need for Unplanned Stenting with the Use of Platelet Glycoprotein IIb/IIIa Blockade in Percutaneous Coronary Intervention. *European Heart Journal* 1998;19:239.

Kereiakes DJ, Smith SC, Jacobs AK, Kern M, Faxon DP. Angioplasty for acute myocardial infarction in community hospital without surgical back-up: response to Wharton and Angelini publications: Should guidelines be changed?: Not whether but when. Letter to editor; *J Am Coll Cardiol* 2000;36:299-300.

Kereiakes DJ, Cox D, Hermiller J, O'Shaughnessy C, Te Riele J, Lansky A, Fink S, Nishimura N, Seivers M. MULTILINK-TETRA: A New Generation Stent Design with Enhanced Clinical Performance. *Am J Cardiol*, 2000; 86:17i.

Kereiakes DJ, Lincoff AM, Achenbach R, Melsheimer R, Kurz M, Califf R, Anderson K, Topol E. Long Term Abciximab Survival Advantage is not Explained by Reduction in Early Major Cardiac Events. *Am J Cardiol*, 2000; 86:13i.

Kukielka GL, **Kereiakes DJ**, Lorenz T, Mueller M, Andrade D, Halsey N, Howard W, Lovejoy S., Phillips DR. Differential Effects of Citrate vs. PPACK Anticoagulants: Implications for Comparing Glycoprotein IIb/IIIa Inhibitors. *Am J Cardiol*, 2000; 86:69i.

Kereiakes DJ, Kleiman NS, Fry E, Lengerich R, Aquilina J, DeLoof M, Mwawasi G, Maresh K, Burkhart M, Broderick T. Dalteparin and abciximab combination for percutaneous coronary intervention: first dose finding trial results *Am J Cardiol*, 2000; 86:73i.

Kereiakes D, Fry E, Barr L, Matthai W, Cohen M, Brodie, Casale P, Christy G, Moliterno D, Zidar J. Enoxaparin-Abciximab Combination For Percutaneous Coronary Intervention: Final Results of the NICE 4 Trial. *Am J Cardiol*, 2000; 86:14i.

Wong SC, Teirstein P, Moses J, Lansky A, Holmes D, Tripuramant P, Jani S, **Kereiakes D**, Kuntz R, Leon MB. Nine-Month Clinical Outcomes After Intravascular Radiation Therapy for In-Stent Restenosis: A Report from the GAMMA II Registry. *Am J Cardiol*, 2000;86:12i.

Kereiakes DJ, Szyniszewski AM, Simon DI, Rogers C, Wahr D, Adelman DC, Chou TM. Coronary photoangioplasty using Motexafin Lutetium (Antrin): Early findings of a Phase I safety trial in patients undergoing stent implantation. *Circulation* 2000;102:II565.

Kereiakes D, Wahr D, Szyniszewski AM, et al. Antrin photoangioplasty: safety results of a phase I trial in patients undergoing intracoronary stent implantation. *Circulation* 2000;102:II585.

Lincoff AM, **Kereiakes DJ**, Mascelli MA, Deckelbaum L, Barnathan E, Patel K, Frederick B, Topol EJ. Abciximab suppresses the rise in plasma levels of inflammatory markers following PTCA. *Circulation* 2000;102:II-330.

Steinhubl SR, Talley JD, **Kereiakes DJ**, Braden GA, Tchong JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Theroux P. Correlates of baseline platelet as measured by the Ultegra-RPFA and its association with the level of platelet inhibition achieved with GPIIb/IIIa inhibitor therapy. Results from the GOLD Study. *Circulation* 2000;102:II-418.

Steinhubl S, Talley JD, **Kereiakes DJ**, Braden GA, Jia G, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Gallo R. Presence of angiographically visible thrombus, but not clinical syndrome, is associated with lower levels of platelet inhibition with a GPIIb/IIIa inhibitor in patients undergoing a percutaneous coronary intervention. Results from the GOLD Study. *Circulation* 2000;102:II-419.

Bhatt DL, Cho LS, Diaz LA, Wolski KE, Chew DP, Rott M, **Kereiakes DJ**. Hypertension is an under-appreciated, significant risk factor for mortality after percutaneous coronary intervention and is favorably affected by abciximab. *Circulation* 2000;102:II-430.

Mazur W, Kaluza GL, Sapp SK, Balog C, Ellis SG, **Kereiakes DJ**. Pre-PCI Procedural Risk Assessment Does Not Predict Abciximab Benefit. *Circulation* 2000;102:II430 .

Young JJ, **Kereiakes DJ**. New strategies for management of acute coronary syndromes in the cardiac catheterization lab. *Journal of Invesitive Cardiology, Clinical Case Update* 2000;2;14.

Seshiah PN, **Kereiakes DJ**, Vasudevan S, Lopes N, Goldschmidt-Clermont PJ. Activated Monocytes Induce Smooth Muscle Cell Death - Role of M-CSF in Coronary Plaque Instability: Molecular Mechanisms in vitro. *JACC* 2001;37:501A.

Kereiakes DJ. Letter to Editor: Diversity of abciximab platelet inhibition (Response to Steinhubl et al. Attainment and maintenance of platelet inhibition through standard

dosing of abciximab in patients undergoing percutaneous coronary intervention. *Circulation* 1999;100:1977-1982). *Circulation* 2000;102:E186.

Wong SC, Teirstein P, Moses J, Tripuraneni P, Kluck B, Jani S, **Kereiakes DJ**, George B, Duffy CI, Leon MB. Predictors of restenosis following gamma radiation for treatment of in-stent stenoses. *J Am Coll Cardiol* 2001;37:54A.

Seshiah PV, **Kereiakes DJ**, Shanker SS, Lopes N, Goldschmidt-Clermont PJ. Activated monocytes induce smooth muscle cell death-role of M-CSF in coronary plaque instability: molecular mechanisms in vitro. *J Am Coll Cardiol* 2001;37:501A.

Furman, MI, Michelson A, Krueger L, Mueller MN, Broderick TM, Schneider J, Howard W, Fox M, Barnard M, Frelinger III A, Furman M, **Kereiakes DJ**. Effects of ½ dose abciximab in the presence of either dalteparin or unfractionated heparin on platelet inhibition, as determined by 3 independent assay. *Thrombosis and Haemostasis Supplement* July 2001 (abstract P382). (Presented at the XVIIIth Congress of the International Society on Thrombosis and Haemostasis, Paris, France, July 8, 2001

Kereiakes D, Michelson A, Krueger L, Mueller M, Broderick T, Schneider J, Howard W, Fox M, Barnard M, Furman M. Randomized comparison of dalteparin vs. UH in combination with abciximab during PCI: effects on leukocyte-platelet aggregation, platelet activation and GP IIb/IIIa receptor expression. *Am J Cardiol* 2001;88:97G.

Kereiakes D, Syzniszewski AM, Hermann HC, Simon DI, Rogers CDK, Kramer PH, Shear W, Yeung AC, Chou TM, Adelman DC. Antrin photoangioplasty for treatment of coronary artery disease: results at 6-month follow-up. *Am J Cardiol* 2001;88:101G

Kereiakes DJ, Michelson AD, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard W, Fox M, Barnard M, Furman MI. Randomized comparison of dalteparin vs. unfractionated in combination with abciximab during percutaneous coronary intervention: effects on leukocyte-platelet aggregation, platelet activation and GP IIb/IIIa receptor expression. *Circ* 2001;104:II-38.

Kereiakes DJ, Anderson KM, Achenbach RE, Melsheimer RM, Kurz MA, Barnathan E. Abciximab survival advantage is not explained by reduction in early major cardiac events: EPIC, EPILOG and EPISTENT 3 year analysis. *Circ* 2001;104:II-87.

Quinn MJ, Lincoff, AM, **Kereiakes DJ**, Kleiman NS, Cohen EA, Ferguson JJ, Tchong JE, Califf RM, Topol EJ. Long-Term Mortality Benefit of Abciximab in Percutaneous Intervention. *Circ* 2001;104:II-387.

Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, Jessell A, **Kereiakes DJ**, Knight J, Thulin L, Theroux P. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high risk CABG surgery patients. Results of the CABG surgery cohort of the GUARDIAN study. *Circ* 2001;104:II-687.

Lincoff AM, Bittl JA, Kleiman NS, **Kereiakes DJ**, Harrington RA, Sarembock IJ, Jackman JD, Mehta S, Maierson EF, Chew DP, Topol EJ for the REPLACE

investigators. The REPLACE 1 Trial: a pilot study of bivalirudin vs. heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade. *J Am Coll Cardiol* 2002;39:16A.

Popma JJ, Cox N, Wahr D, Hermann H, Simon DI, Rogers CD, Kramer P, Shear W, Shunk K, Yeung A, Prpic R, Adelman D, **Kereiakes D**. A quantitative assessment of regional changes in lumen diameter after photodynamic therapy with motexafin lutetium in patients undergoing stent implantation. *J Am Coll Cardiol* 2002;39:26A.

Steinhubl SR, Saucedo JF, Sane DC, Berger PB, Moliterno DJ, Tchong JE, **Kereiakes DJ**. Point-of-care measurement of platelet function before angioplasty strongly predicts future target vessel revascularization. *J Am Coll Cardiol* 2002;39:72A.

Vasudevan SS, Seshiah PN, **Kereiakes D**, Goldschmidt-Clermont PJ. Monocyte-induced killing of vascular smooth muscle cells: is M-CSF the final common pathway. *J Am Coll Cardiol* 2002;39:256A.

Kereiakes DJ, Rabinowitz AC, Ammar R, Young JJ, Vinekar C, Rogers C. First multi-center experience with a novel, low-profile filter-wire distal protection device (Interceptor) during saphenous vein graft stenting. *Am J Cardiol* 2002;90:26H

Kereiakes DJ, Szyniszewski A, Hermann HC, Simon DI, Rogers C, Kramer P, Shear W, Yeung A, Shunk K, Chou T, Popma J, Fitzgerald P, Carroll T, Forer D, Adelman D. Optimizing drug and light dose for Antrin phototherapy during percutaneous coronary stenting. *Am J Cardiol* 2002;90:156H.

Kereiakes DJ, Mehra A, Morales C, Magorien R, Popma J, Mazzoni M, Waksman R. Multi-center study of a novel IR192 vascular brachytherapy device to treat in-stent restenosis: final results of the ARTISTIC II trial. *Am J Cardiol* 2002;90:102H

Cox D, **Kereiakes D**, Hermiller J, Midei M, Bachinsky W, Nukta D, Lansky A, Fink S, Marin L, Linnemeier TL. First use of a novel cobalt chrome coronary stent alloy in man: favorable late outcomes from the Guidant Multi-link VISION stent registry. *Am J Cardiol* 2002;90:15(H).

Morneault J, **Kereiakes DJ**, Wright CB. Economic impact of drug eluting stents in a multiple hospital healthcare system. *Am J Cardiol* 2002;90:4H

Low R, Takedo P, Feldman R, Cox D, Midei M, Bergin P, Hermiller J, **Kereiakes D**, Popma J, Lasala J. Incidence of creatine kinase and creatine kinase-MB and troponin I and troponin T elevation after elective stenting in the VICTORY Trial with EXPRESS stent. *Am J Cardiol* 2002;90:152H.

Chung ES, Packer M, Batra S, Lo KH, **Kereiakes DJ**, Willerson JT. Randomized, placebo-controlled trial of infliximab, a monoclonal antibody to tumor necrosis factor-A in heart failure. *Circ* 2002;106: II-470.

Vasudevan SS, Lopes NH, Seshiah PN, Wang T, Marsh CB, **Kereiakes DJ**, Dong C, Goldschmidt PJ. M-CSF induced killing of smooth muscle cells by monocytes: roles of monocytes agglutination and the Fas death receptor pathway. *Circ* 2002;106:II-242.

Moses JW, Leon MB, Popma JJ, Caputo R, O'Shaughnessy C, Brown C, **Kereiakes D**, Williams DO, Teirstein PS, Kuntz RE. A multicenter randomized clinical study of the sirolimus-eluting stent in native coronary lesions: clinical outcomes. *Circ* 2002;106:II-392

Young JJ, Mazzaferri EL. Episodic myalgia, weakness and dark urine. *Hospital Practice*. 2000; Jan. 15; 35(1):140-143.

Young JJ, Mazzaferri EL. Acute chest pain after laparotomy. *Hospital Practice*. 2000; Mar. 15; 35(3):123-130.

Young JJ, Kereiakes DJ. Combination low-molecular-weight heparin and glycoprotein IIb/IIIa inhibition during coronary intervention. *Acute Coronary Syndromes*. 2000;3(2):62-66.

Young JJ, Kereiakes DJ. Low-molecular-weight heparins: current status for use in acute coronary syndromes and percutaneous coronary intervention. *Acute Coronary Syndromes*. 2000;3(3):74-82.

Young JJ, Kereiakes DJ. New strategies for management of acute coronary syndromes in the cardiac catheterization lab. *J Invasive Cardiol*. 2000;2(14):suppl.

Young JJ, Kereiakes DJ. Abciximab: cost-effective survival advantage in clinical trials and clinical practice. *Am Heart J*. 2000;140:S148-53.

Kereiakes DJ, **Young JJ**, Broderick TM, Shimshak TM, Abbottsmith CW. Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute coronary syndromes. *Am J Cardiol*. 2000;86(suppl):10M-17M.

Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. *J Invasive Cardiol*. 2000;12(suppl E):E14-E18.

Kereiakes DJ, **Young JJ**, Runyon JP, Shimshak TM. Ticlopidine monotherapy following coronary stent deployment: "Penny wise and pound foolish". *J Invasive Cardiol*. 2001;13:437-8.

Kandzari DE, Behar VS, Sketch MH, Kereiakes DJ, Shimshak T, Broderick T, **Young J**, Runyon JP, Safian RD, Kern M, Colombo A. Extensive thrombus prior to elective percutaneous coronary intervention. *J Invasive Cardiol*. 2001;13:538-42.

Kereiakes DJ, Lorenz T, **Young JJ**, Kukielka G, Mueller MN, Nanniazzi-Alaimo L, Phillips DR. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatid and tirofiban. *J Thromb Thrombolysis*. 2001;12:123-7.

Young JJ, Kereiakes DJ. Low-molecular-weight heparin in percutaneous coronary intervention: ready for prime time? *ACC Current Journal Review*. Mar/Apr. 2002:59-64.

Kereiakes DJ, Choo JK, **Young JJ**, Broderick TM. Combination antiplatelet therapy following brachytherapy with restenting: "It ain't over 'til the fat lady sings". *J Invasive Cardiol.* 2002;14:115-7.

Young JJ, Kereiakes DJ. Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice. *J Interv Cardiol.* 2002;15:115-20.

Kereiakes DJ, **Young JJ**, Choo JK, Broderick TM. Intra-graft verapamil: "an ounce of prevention is worth a pound of cure". *J Invasive Cardiol.* 2002;14:303-4.

Young JJ, Kereiakes DJ. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: "IIb or not IIb, what is the question?". *J Invasive Cardiol.* 2002;14:404-10

Choo JK, **Young JJ**, Kereiakes DJ. A guide to drug use during percutaneous coronary intervention. *Drugs.* 2002;62:2589-601.

Dave RJ, Sachdev S, Dippel E, Tramuta D, **Young JJ**, Runyon JP, Shimshak TM. Improved one year patency rates for lengthy superficial femoral artery chronic total occlusions using conventional angioplasty techniques and nitinol stenting. Presented at the Global Endovascular Therapy Conference, Monte Carlo, 2001.

Yadav JS, Moliterno DJ, Whitlow PL, Almany SL, Ajluni SC, Choksi NA, Bowers TR, Kahn JK, Castaneda F, Brady TM, Swischuk JL, Smouse HB, Hartigan AS, Shimshak TM, **Young JJ**, Davis TP, LaLonde TA, Benenati JF, Zemel G, Powell A, Roberts JS, Quesada R, DeFranco AC, Harris JL, Chambers JL, Rutherford BD, Johnson WL, Mewissen MW, Cummins FE. A randomized trial comparing the QuickSeal arterial closure device to manual compression following interventional and diagnostic catheterization procedures. Presented at TCT in Washington, D.C., September 2001.

Chow T, Booth T, Schloss EJ, Waller T, Chung E, Ibanez K, Choo J, Menon S, **Young J**, Kereiakes D. Routine microvolt T-wave alternans screening predicts inducible ventricular arrhythmias. Presented at Cardiostim in Nice, France, June 18, 2002.

Chow T, Booth T, Schloss EJ, Waller T, Chung E, Ibanez K, Choo J, Menon S, **Young J**, Kereiakes D. The spectrum of T-wave alternans in patients with coronary artery disease. Presented at Cardiostim in Nice, France, June 18, 2002.

Chow T, Booth T, Schloss EJ, Waller T, Chung E, Ibanez K, Choo J, Menon S, **Young J**, Kereiakes D. Limitations of an accelerated ventricular stimulation protocol. Presented at Cardiostim in Nice, France, June 18, 2002.

Young JJ, Abbottsmith CW, Broderick TM, Choo JK, Runyon JP, Schneider JF, Shimshak TM, Kereiakes DJ. Durable clinical benefit following SR90 beta irradiation therapy for in-stent restenosis in community hospital practice. Presented at TCT in Washington, D.C., September 2002.

Kereiakes DJ, Rabinowitz AC, Ammar R, **Young JJ**, Vinekar C, Rogers C. First multi-center experience with a novel, low-profile filter-wire distal protection device (Interceptor) during saphenous vein graft stenting. *Am J Cardiol.* 2002;90:26H.

Lorbar M, Skalova K, Nabi A, **Chung ES**, Fenton RA, Dobson JG Jr, Meyer TE. Norepinephrine concentrations in the epicardial transudate reflect early changes in

adrenergic activity in the isolated perfused heart. *J Mol Cell Cardiol.* 2000 Sep;32(9):1695-701

Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, **Chung ES**, Meyer TE, Norton GR. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. *Circulation.* 2001 Jan 2;103(1):155-60.

Meyer TE, **Chung ES**, Perlini S, Norton GR, Woodiwiss AJ, Lorbar M, Fenton RA, Dobson JG. Antiadrenergic Effects of Adenosine in Pressure Overload Hypertrophy. *Hypertension.* 2001 Mar;37(3):862-868.

Fenton RA, **Chung ES**. Chronic ethanol enhances adenosine antiadrenergic actions in the isolated rat heart. *Alcohol Clin Exp Res.* 2001 Jul;25(7):968-75.

Norton GR, Woodiwiss AJ, Gaasch WH, Mela T, **Chung ES**, Aurigemma GP, Meyer TE. Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. *J Am Coll Cardiol.* 2002 Feb 20;39(4):664-71.

T Chow, T Booth, E Schloss, et. al. The spectrum of microvolt T-wave alternans in patients with coronary artery disease. *Europace*, 185P-12, 2002 (abstract)

T Chow, T Booth, E Schloss, et. al. Routine microvolt T-wave alternans screening predicts inducible ventricular arrhythmias. *Europace*, 185P-11, 2002 (abstract)

T Chow, T Booth, E Schloss et. al. Limitations of an acceleration ventricular stimulation protocol. *Europace*, 152P-43, 2002 (Abstract)

Book Chapters:

Kereiakes DJ. Platelet GP II/IIIa inhibition-device synergy during percutaneous coronary intervention. In Ferguson JJ, Chronos NAF, Harrington RA (eds). *Antiplatelet Therapy in Clinical Practice.* Martin Dunitz Publisher, 2000.

Pelberg, Robert A, Antevil, Jared L. Cardiac Imaging. *Radiology Recall.* Gay, Spencer. Lippincott Williams and Wilkins, 2000.

Kereiakes DJ, Shimshak TM. Adjunctive Pharmacology During Percutaneous Coronary Intervention. In Antman E (ed) *Cardiovascular Therapeutics*, 2nd Edition. W.B. Saunders. 2001.

Kereiakes DJ, Shimshak TM. Coronary artery revascularization: adjunctive pharmacology in the percutaneous approach. In Lanzer P, Topol EJ (eds). *Pan Vascular Medicine.* Springer-Verlag Berlin Heidelberg New York 2002.

Archer TP, **Young JJ**, Mazzaferri EL. Morning Report: Internal Medicine. McGraw-Hill Publishing Companies, Inc., New York, NY. 2000, **Co-Author**.

The Little Heart Book. Robertson & Fisher Publishing Co., Cincinnati, Ohio. 2001, **Co-Editor**.

The Little Book on Congestive Heart Failure. Robertson & Fisher Publishing Co., Cincinnati, Ohio. 2001, **Co-Editor**.

Dave RM, Sachdev S, **Young JJ**, Shimshak TM. Aortoiliac bifurcation stent placement. In White CJ (ed). Peripheral Vascular Interventions. Martin Dunitz Publisher, 2002, pp 153-157.

PROGRAMS FOR PHYSICIANS:

September 12-14, 2000 The Second Annual "PRIMER ON PERIPHERAL ARTERIAL DISEASE – AN INTERVENTIONAL COURSE FOR ADVANCED ANGIOPLASTY FELLOWS"

Kingsgate Marriott Conference Center

September 15-16, 2000 The HEART 2000 - "A Comprehensive Cardiology Update for Primary Care Physicians"

Kingsgate Marriott Conference Center

Saturday, October 27, 2001 The Heart 2001 Series – "Second Annual Clinical Cardiology Update for Primary Care Physicians"
Kingsgate Marriott Conference Center

November 28-29, 2001 Peripheral Endovascular Techniques – PET Course
"Third Annual Program for Advanced Interventional Cardiology"
Kingsgate Marriott Conference Center

Saturday, October 19, 2002 THE HEART 2002 – Third Annual Clinical Cardiology Update for Physicians, Nurses, and Allied Health Professionals"
The Kingsgate Marriott Conference Center

PROGRAMS FOR THE PUBLIC:

April 28, 2001 "Living With Heart Failure"
The Christ Hospital Auditorium

August 22, 2001 "From Palpitations to Fainting – Atrial Fibrillation; Diagnosis, Management & New Frontiers"
The Christ Hospital Auditorium

August 29, 2001	“Cardiovascular Disease In The New Millennium – Cardiovascular Disease: Scope of the Problem” The Christ Hospital Auditorium
September 6, 2001	“Living With Heart Failure – Medical Management of Heart Failure; A discussion About Medications: Congestive Heart Failure Program” The Christ Hospital Auditorium
April 3, 2002 April 10, 2002 April 17, 2002	“Living Well With Heart Disease – A 3-Part Education Series for People Who Care About Their Health” The Christ Hospital Auditorium HEART FAILURE (04/03/02) CARDIOVASCULAR DISEASE TODAY (4/10/02) MANAGEMENT OF HEART RHYTHM PROBLEMS (04/17/02)
August 6, 2002	“HEART MATTERS – New Heart Information for everyone” The Christ Hospital Auditorium

**PRECEPTORSHIP TRAINING PROGRAMS
2001 PRECEPTORSHIPS**

Program Dates	Sponsor	Participants Name
January 1-31, 2001 thru March 31, 2001	Boston Scientific 90-Day	- Rajesh Dave', M.D.
January 10-11, 2001	Boston Scientific	- Kingson Mohmah, M.D. - Alan Simon, M.D.
January 24-25, 2001	GUIDANT	- Andrew Goldman, M.D.
January 31-Feb 1, 2001	Cordis	- Charles Dow, M.D. - Jack Flyer, M.D.
February 7-8, 2001	Cordis	- Doug Bogart, M.D.
February 14-15, 2001	Cordis	- Trilock Sharma, M.D.
February 21-22, 2001	Boston Scientific	- Dan Dullas, M.D. - David Brown, M.D.
March 7-8, 2001	GUIDANT	- Visha Bhoopalam, M.D. - Robert Starrett, M.D.
March 21-22, 2001	Cordis	- Matthew Luken, M.D.
April 1, 2001 thru June 30, 2001	Boston Scientific 90- Day	- Mark Smucker, M.D.
April 4-5, 2001	Boston Scientific	- Soo Park, M.D. - Simon Gorwara, M.D.
April 18-19, 2001	GUIDANT	Cancelled
May 2-3, 2001	Cordis	- David Williams, M.D.
May 30-31, 2001	GUIDANT	- Paul Gordon, M.D. - Hamed Taheri, M.D.
June 13-14, 2001	GUIDANT	- Hamed Taheri, M.D.
July 11-12, 2001	GUIDANT	- Adell Shaheen, M.D. - Kevin Silver, M.D.
July 2, 2001 through August 10, 2002	Independent (Private Pathway / OHHC)	- Sumeet Sachdev, M.D.
July 25-26, 2001	CORDIS	- Dr. Krolick - Dr. Julius Gasso
August 8-9, 2001	Boston Scientific	- Richard Stewart, M.D. - Anthony Fletcher, M.D.
August 22-23, 2001	GUIDANT	- Paul Gordon, M.D. - Simon Jung, M.D.
September 01, 2001 thru September 30, 2001	Boston Scientific 30-Day	- Kenneth Gibbs, M.D.
September 5-6, 2001	CORDIS	- Dr. Ahmed Habib - Dr. George Pierson
September 19-20, 2001	Boston Scientific	- Dr. Robert Starrett - Dr. Kingson Mohmah, MD
October 1, 2001 thru November 30, 2001	Boston Scientific 60-Day	- Thomas Wolford, M.D.
October 17-18, 2001	CORDIS	- Dr. Posada - Dr. Nassif

October 31-November 01, 2001	Boston Scientific	- Dr. Mark Miller - Open
December 5-6, 2001	CORDIS	- Dr. Eric Gerrar - Dr. James Spadaro
December 14-13, 2001	Boston Scientific	- Kingston Mohmah, M.D. - Roger Wittum, M.D.
December 19-20, 2001	Boston Scientific	- Dr. Jeffrey Rubenstein - Dr. Claude Brachfield
YEARLY TOTALS		44 Participants

2002 PRECEPTORSHIPS

Program Dates	Sponsor	Participants Name
February 20-21, 2002	GUIDANT	- Dr. Jhangianai
March 6-7, 2002	Boston Scientific	- Dr. McCord - Dr. Ayoubi
March 20-21, 2002	CORDIS	- Dr. Kamran - Dr. Reich
April 3-4, 2002	GUIDANT	- Dr. Nazir - Dr. C. G. Reddy
April 17-18, 2002	Boston Scientific	- Dr. Vallabhaneni
May 8-9, 2002	CORDIS	- Dr. Tallal Attar - Dr. Monica Hunter
May 22-23, 2002	Boston Scientific	- Dr. Richard Stewart - Dr. Sinha
June 5-6, 2002	GUIDANT	- Dr. Goyal - Dr. Khanal
June 19-20, 2002	Boston Scientific	- Dr. MacPhail - Dr. Marshall
August 7-8, 2002	GUIDANT	- Dr. Pierre Bamdad - Dr. Frederick Stockton
August 28-29, 2002	CORDIS	- Dr. Tehrani - Dr. Hassan Rajjoub
September 11-12, 2002	Boston Scientific	- Dr. Rinder - Dr. Jeff Goldstein
October 9-10, 2002	CORDIS	- Dr. Simon Gorwara
October 23-24, 2002	GUIDANT	- Dr. Maraboyina - Dr. Pierre Bamdad
November 6-7, 2002	Boston Scientific	- Dr. Pasi
November 14-15, 2002	Medtronic	- Dr. Mio Stikovac - Dr. Michael Hughes
November 20-21, 2002	CORDIS	- Dr. Jeffery Goldstein - Dr. Sohail Ikram
December 4-5, 2002	GUIDANT	- Dr. David Schreiber - Dr. Mio Stikovac
December 18, 2002	SCI-MED IVUS Program	- Dr. Pierre Bomdad
YEARLY TOTALS		33 Participants

